persistently colonizes the nasopharynx of humans, which increases the risk for invasive diseases such as skin infection and bacteremia. Nasal colonization triggers IgG responses against staphylococcal surface antigens, however these antibodies cannot prevent subsequent colonization or disease. Here we describe WU1, a multi-locus sequence type ST88 isolate, that persistently colonizes the nasopharynx of mice. We report that staphylococcal protein A (SpA) is required for persistence of WU1 in the nasopharynx. Compared to animals colonized by wild-type , mice colonized with the Δ variant mount increased IgG responses against staphylococcal colonization determinants. Immunization of mice with a non-toxigenic SpA variant, which cannot crosslink B cell receptors and divert antibody responses, elicits protein A-neutralizing antibodies that promote IgG responses against colonizing and diminish pathogen persistence. persistently colonizes the nasopharynx of about a third of the human population, thereby promoting community- and hospital-acquired infections. Antibiotics are currently used for decolonization of individuals at increased risk of infection. However, the efficacy of antibiotics is limited by recolonization and selection for drug-resistant strains. Here we propose a model whereby staphylococcal protein A (SpA), a B cell superantigen, modifies host immune responses during colonization to support continued persistence of in the nasopharynx. We show that this mechanism can be thwarted by vaccine-induced anti-SpA antibodies that promote IgG responses against staphylococcal antigens and diminish colonization.